Artificial neural networks for prostate carcinoma risk assessment

No abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/34357/1/1178_ftp.pd

Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer

Advanced or metastatic gastric cancer, which is one of the most common malignancies in Korea, is difficult to cure by surgery alone and generally requires combination chemotherapy. Paclitaxel is active against gastric cancer and when combined with 5-fluorouracil/leucovorin and/or cisplatin is effective in the treatment of gastric cancer. We attempted to determine the effect and safety with the combination of paclitaxel with split cisplatin and 5-fluorouracil/leucovorin in advanced or metastatic gastric cancer. Patients with histologically-proven locally advanced/metastatic or recurrent gastric cancer with an ECOG performance status 0-2 were enrolled. The patients received 135 mg/m(2) of paclitaxel as a 3-h intravenous infusion on day 1 and 5-fluorouracil (1200 mg/m(2)) plus leucovorin (20 mg/m(2)) as an intravenous infusion over 12 h plus cisplatin (30 mg/m(2)) by continuous intravenous infusion on days 1-3, every 21 days. Between September 2003 and April 2005, 30 patients (26 evaluable patients) with a median age of 57 years (range 34-74) were enrolled and underwent 111 completed treatment cycles (a median of 3 cycles per patient). Of the evaluable patients, 12 patients showed a partial response and 8 patients had stable disease. The overall response rate was 46.2%. The median progression-free survival was 5.6 months (95% Cl. 3.76-7.4 months), and the median overall survival was 9.6 months (95% CI. 6.67-12.47 months). The hematologic and non-hematologic toxicities were tolerable. The grade III and IV hematologic toxicities were anemia (6.8%) and neutropenia (2.6%). Febrile neutropenia was observed in I patients and I cycle. Other hematologic toxicities and grade Ill and IV non-hematologic toxicities, except nausea (66.7%) and vomiting (33.3%) were uncommon and not severe. TPFL combination chemotherapy is effective and tolerable with acceptable toxicities in patients with advanced/metastatic, recurrent gastric cancer.Kim JG, 2007, CANCER CHEMOTH PHARM, V60, P863, DOI 10.1007/s00280-007-0433-8Pinto C, 2007, ANN ONCOL, V18, P510, DOI 10.1093/annonc/mdl459Shah MA, 2006, J CLIN ONCOL, V24, P5201, DOI 10.1200/JCO.2006.08.0887Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429Chao Y, 2006, BRIT J CANCER, V95, P159, DOI 10.1038/sj.bjc.6603225Wagner AD, 2006, J CLIN ONCOL, V24, P2903, DOI 10.1200/JCO.2005.05.0245Cho BC, 2006, ONCOL REP, V15, P621Jeung HC, 2006, ONCOLOGY-BASEL, V70, P63, DOI 10.1159/000091186Yeh KH, 2005, ONCOLOGY-BASEL, V69, P88, DOI 10.1159/000087304Omura GA, 2003, J CLIN ONCOL, V21, P2843, DOI 10.1200/JCO.2003.10.082Rothenberg ML, 2003, NAT REV CANCER, V3, P303, DOI 10.1038/nrc.1047Gadgeel SM, 2003, AM J CLIN ONCOL-CANC, V26, P37Louvet C, 2002, J CLIN ONCOL, V20, P4543, DOI 10.1200/JCO.2002.02.021Honecker F, 2002, ANTI-CANCER DRUG, V13, P497LEE HJ, 2002, GASTRIC CANCER, V5, P177CONSTENLA M, 2002, GASTRIC CANC, V5, P142Kollmannsberger C, 2000, BRIT J CANCER, V83, P458Vanhoefer U, 2000, J CLIN ONCOL, V18, P2648Yoo CH, 2000, BRIT J SURG, V87, P236Murad AM, 1999, AM J CLIN ONCOL-CANC, V22, P580Grem JL, 1999, BIOCHEM PHARMACOL, V58, P477Lokich JJ, 1999, CANCER, V85, P2347Rowinsky EK, 1999, CLIN CANCER RES, V5, P767Kim YH, 1999, CANCER, V85, P295Ajani JA, 1998, CANCER J SCI AM, V4, P269Cascinu S, 1998, ANTI-CANCER DRUG, V9, P307Bokemeyer C, 1997, ANTI-CANCER DRUG, V8, P396Glimelius B, 1997, ANN ONCOL, V8, P163Webb A, 1997, J CLIN ONCOL, V15, P261BOKEMEYER C, 1997, SEMIN ONCOL, V24Ychou M, 1996, EUR J CANCER, V32A, P1933Schipper DL, 1996, ANTI-CANCER DRUG, V7, P137Chang YF, 1996, CANCER, V77, P14KWAN HC, 1995, CANCER, V76, P2186ZANIBONI A, 1995, CANCER, V76, P1694VANHOEFER U, 1994, ANN ONCOL, V5, P850KIM NK, 1993, CANCER, V71, P3813OKADA Y, 1991, ANTI-CANCER DRUG, V2, P453JOHNSON PWM, 1991, BRIT J CANCER, V64, P603WILS JA, 1991, J CLIN ONCOL, V9, P827PREUSSER P, 1989, J CLIN ONCOL, V7, P1310POSNER MR, 1987, CANCER, V59, P15BELLIVEAU JF, 1986, CANCER TREAT REP, V70, P1215SALEM P, 1984, CANCER, V53, P837WEISS GB, 1983, CONTROL CLIN TRIALS, V4, P43SALEM P, 1978, CANCER TREAT REP, V62, P1553DREWINKO B, 1973, CANCER RES, V33, P3091